Plus Therapeutics, Inc.

How big is Plus Therapeutics, Inc.?

As of Jun 18, Plus Therapeutics, Inc. has a market capitalization of 10.18 million, with net sales of 5.21 million and a net profit of -27.11 million over the last four quarters. The company reported shareholder's funds of -8.95 million and total assets of 6.63 million as of Dec 24.

Market Cap: As of Jun 18, Plus Therapeutics, Inc. has a market capitalization of 10.18 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Plus Therapeutics, Inc. reported net sales of 5.21 million and a net profit of -27.11 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -8.95 million and total assets of 6.63 million.

What does Plus Therapeutics, Inc. do?

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing cancer treatments, with a market cap of $10.18 million and recent quarterly net sales of $1 million and a net loss of $17 million.

Overview:<BR>Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cancer patients, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 10.18 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.42 <BR>Return on Equity: 99.95% <BR>Price to Book: -0.43 <BR><BR>Contact Details:<BR>Address: 4200 Marathon Blvd Ste 200, AUSTIN TX: 78756-3433 <BR>Tel: 1 858 4580900 <BR>Website: http://www.plustherapeutics.com/

Should I buy, sell or hold Plus Therapeutics, Inc.?

Who are in the management team of Plus Therapeutics, Inc.?

As of March 2022, the management team of Plus Therapeutics, Inc. includes Chairman Richard Hawkins, CEO Dr. Marc Hedrick, and Independent Directors Howard Clowes, Robert Lenk, Greg Petersen, and Annigje van Es-Johansson, who oversee the company's strategic direction and operations.

As of March 2022, the management team of Plus Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Richard Hawkins, Chairman of the Board<BR>- Dr. Marc Hedrick, Chief Executive Officer and Director<BR>- Mr. Howard Clowes, Independent Director<BR>- Dr. Robert Lenk, Independent Director<BR>- Mr. Greg Petersen, Independent Director<BR>- Dr. Annigje van Es-Johansson, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is Plus Therapeutics, Inc. overvalued or undervalued?

As of August 14, 2023, Plus Therapeutics, Inc. has been downgraded to a risky valuation grade due to negative financial ratios and significant underperformance, with a year-to-date return of -62.51% compared to the S&P 500's 12.22%.

As of 14 August 2023, the valuation grade for Plus Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant downgrade in its financial standing. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -0.45 and an EV to EBITDA of -0.06, which highlight its struggles in generating positive value. Comparatively, peers like Sonoma Pharmaceuticals, Inc. have a P/E ratio of -2.1124 and Petros Pharmaceuticals, Inc. at -0.1676, reinforcing the challenging environment within the industry.<BR><BR>The stock has underperformed significantly against the S&P 500, with a year-to-date return of -62.51% compared to the index's 12.22%, and a staggering decline of -99.02% over the past five years. This stark contrast in performance further supports the conclusion that Plus Therapeutics, Inc. is overvalued in its current state.

Is Plus Therapeutics, Inc. technically bullish or bearish?

As of September 8, 2025, Plus Therapeutics, Inc. shows a mildly bearish trend due to bearish signals from daily moving averages and weekly Bollinger Bands, despite some mixed bullish indicators from the MACD and KST.

As of 8 September 2025, the technical trend for Plus Therapeutics, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven primarily by the daily moving averages indicating bearishness and the weekly Bollinger Bands also showing a bearish signal. While the MACD is mildly bullish on both weekly and monthly time frames, the overall sentiment is tempered by the bearish signals from the Bollinger Bands and daily moving averages. The KST shows a mixed picture with weekly bullishness but monthly bearishness, and the Dow Theory indicates a mildly bullish stance on both time frames. There is no available return data to compare the company's performance against the S&P 500.